Who are Fintepla's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levadil, Cardura, Sudafed PE, Phenergan Vc W/ Codeine, Epinephrin, Epirenamine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fenfluramine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Fintepla — Competitive Intelligence Brief

Fintepla (FENFLURAMINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: fenfluramine. Area: Metabolic.

marketed fenfluramine Alpha-1B adrenergic receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Fintepla (FENFLURAMINE) — UCB. Fintepla works by binding to the Alpha-1B adrenergic receptor, which helps regulate the activity of certain neurons in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fintepla TARGET	FENFLURAMINE	UCB	marketed	fenfluramine	Alpha-1B adrenergic receptor	2020-01-01
Levadil	DILEVALOL		marketed	dilevalol	Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Beta-1 adrenergic receptor	1990-01-01
Cardura	DOXAZOSIN	Viatris	marketed	alpha-Adrenergic Blocker	Alpha-1B adrenergic receptor	1990-01-01
Sudafed PE	phenylephrine	Generic (multiple manufacturers)	marketed	Alpha-1 adrenergic agonist (decongestant/vasopressor)	Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor	1976-01-01
Phenergan Vc W/ Codeine	PHENYLEPHRINE BITARTRATE	ANI Pharmaceuticals	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Alpha-1B adrenergic receptor	1952-01-01
Epinephrin	Epinephrin	United States Naval Medical Center, San Diego	marketed		Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor
Epirenamine	racepinefrine		marketed	racepinefrine	Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-10-23 — Phenergan Vc W/ Codeine · 9066856 · US
2033-10-23 — Phenergan Vc W/ Codeine · 9486406 · US
2033-10-23 — Phenergan Vc W/ Codeine · 9855246 · US
2033-11-14 — Phenergan Vc W/ Codeine · 8859623 · US
2034-04-23 — Phenergan Vc W/ Codeine · 9486406*PED · US
2034-04-23 — Phenergan Vc W/ Codeine · 9066856*PED · US
2036-08-05 — Phenergan Vc W/ Codeine · 11471400 · US
2036-09-26 — Phenergan Vc W/ Codeine · 11213480 · US

Sponsor landscape (fenfluramine class)

UCB · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fintepla — Competitive Intelligence Brief. https://druglandscape.com/ci/fenfluramine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab